Dragonfly Therapeutics, Inc., a Waltham, MA-based clinical-stage biopharmaceutical company, raised a new funding round.
The amount of the deal was not disclosed.
Fidelity Management & Research Company has led a new round of investment, along with other major investors. This brings total equity funding plus partnership capital in the company to over $300 million thus far, with potential future milestones of over $10 billion plus ongoing royalties.
The company intends to use the funds to further accelerate development of its novel innate immune system and Natural Killer cell-based immunotherapies into the clinic.
Led by Bill Haney, co-founder and CEO, Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body’s innate immune system to bring breakthrough disease treatments to patients.